Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Granuloma annulare associated with immune checkpoint inhibitors.

Literature DB >> 28983973

Granuloma annulare associated with immune checkpoint inhibitors.

J Wu^1,2,3, B Y Kwong⁴, K J Martires⁴, K E Rieger^4,5, W H Chung^2,3, G V Iyer^6,7, M E Lacouture¹.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2017 PMID： 28983973 PMCID： PMC5867195 DOI： 10.1111/jdv.14617

Source DB: PubMed Journal: J Eur Acad Dermatol Venereol ISSN： 0926-9959 Impact factor: 6.166

× No keyword cloud information.

8 in total

Review 1. Granuloma Annulare.

Authors: Emily Louise Keimig
Journal: Dermatol Clin Date: 2015-05-13 Impact factor: 3.478

2. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.

Authors: Jarushka Naidoo; Katja Schindler; Christiane Querfeld; Klaus Busam; Jane Cunningham; David B Page; Michael A Postow; Alyona Weinstein; Anna Skripnik Lucas; Kathryn T Ciccolini; Elizabeth A Quigley; Alexander M Lesokhin; Paul K Paik; Jamie E Chaft; Neil H Segal; Sandra P D'Angelo; Mark A Dickson; Jedd D Wolchok; Mario E Lacouture
Journal: Cancer Immunol Res Date: 2016-02-29 Impact factor: 11.151

Review 3. Granuloma annulare: Pathogenesis, disease associations and triggers, and therapeutic options.

Authors: Evan W Piette; Misha Rosenbach
Journal: J Am Acad Dermatol Date: 2016-09 Impact factor: 11.527

4. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Authors: Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Journal: Lancet Oncol Date: 2009-12-08 Impact factor: 41.316

5. Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma.

Authors: Namrata Nayar; Karen Briscoe; Pablo Fernandez Penas
Journal: J Immunother Date: 2016-04 Impact factor: 4.456

6. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.

Authors: Morganna Freeman-Keller; Youngchul Kim; Heather Cronin; Allison Richards; Geoffrey Gibney; Jeffrey S Weber
Journal: Clin Cancer Res Date: 2015-10-07 Impact factor: 12.531

Review 7. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.

Authors: V R Belum; B Benhuri; M A Postow; M D Hellmann; A M Lesokhin; N H Segal; R J Motzer; S Wu; K J Busam; J D Wolchok; M E Lacouture
Journal: Eur J Cancer Date: 2016-04-01 Impact factor: 9.162

8. Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma.

Authors: Mathew R Birnbaum; Michelle W Ma; Sarah Fleisig; Stuart Packer; Bijal D Amin; Mark Jacobson; Beth N McLellan
Journal: JAAD Case Rep Date: 2017-04-14

8 in total

4 in total

4. Association of Granuloma Annulare With Type 2 Diabetes, Hyperlipidemia, Autoimmune Disorders, and Hematologic Malignant Neoplasms.

Authors: John S Barbieri; Misha Rosenbach; Olaf Rodriguez; David J Margolis
Journal: JAMA Dermatol Date: 2021-07-01 Impact factor: 11.816